🏢
🌐 Entity
Nirsevimab
Monoclonal antibody used as vaccine against RSV
📊 Rating
1 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Public Health (1)
- Pediatrics (1)
- Epidemiology (1)
🏷️ Keywords
RSV (1) · respiratory syncytial virus (1) · pediatric health (1) · monoclonal antibody (1) · Beyfortus (1) · public health (1) · seasonal virus (1)
📖 Key Information
Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.
The most common side effects are rash, fever and injection site reactions (such as redness, swelling and pain where the injection is given).
📰 Related News (1)
-
🇺🇸 RSV season runs into springClick in for more news from The Hill {beacon} View Online Health Care Health Care The Big Story An unusually late RSV season runs into spring A la...
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Nirsevimab:
-
🌐
RSV · 1 shared articles